Palmitic acid analogs exhibit nanomolar binding affinity for the HIV-1 CD4 receptor and nanomolar inhibition of gp120-to-CD4 fusion.

Center for Immunology and Microbial Disease, Albany Medical College, Albany, New York, USA.
PLoS ONE (Impact Factor: 3.53). 08/2010; 5(8):e12168. DOI: 10.1371/journal.pone.0012168
Source: PubMed

ABSTRACT We recently reported that palmitic acid (PA) is a novel and efficient CD4 fusion inhibitor to HIV-1 entry and infection. In the present report, based on in silico modeling of the novel CD4 pocket that binds PA, we describe discovery of highly potent PA analogs with increased CD4 receptor binding affinities (K(d)) and gp120-to-CD4 inhibition constants (K(i)). The PA analogs were selected to satisfy Lipinski's rule of drug-likeness, increased solubility, and to avoid potential cytotoxicity.
PA analog 2-bromopalmitate (2-BP) was most efficacious with K(d) approximately 74 nM and K(i) approximately 122 nM, ascorbyl palmitate (6-AP) exhibited slightly higher K(d) approximately 140 nM and K(i) approximately 354 nM, and sucrose palmitate (SP) was least efficacious binding to CD4 with K(d) approximately 364 nM and inhibiting gp120-to-CD4 binding with K(i) approximately 1486 nM. Importantly, PA and its analogs specifically bound to the CD4 receptor with the one to one stoichiometry.
Considering observed differences between K(i) and K(d) values indicates clear and rational direction for improving inhibition efficacy to HIV-1 entry and infection. Taken together this report introduces a novel class of natural small molecules fusion inhibitors with nanomolar efficacy of CD4 receptor binding and inhibition of HIV-1 entry.


Available from: Alexander Shekhtman, Jun 17, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: The essential oils were obtained from Myosotis arvensis L. and M. palustris L. by hydrodistillation and subsequently analyzed by GC–MS. Fifteen components in M. arvensis and twenty-one in M. palustris representing, respectively, 89.63 and 93.19 % of the total oils were identified on the basis of their retention time, mass spectra characteristics and semi-quantitative data were obtained from relative peak area percentages. The 3-methyl-benzaldehyde was found to be the major constituent of both tested oils (42.76 % in M. arvensis and 45.80 % in M. palustris). Additionally, methyl salicylate was a characteristic compound for M. arvensis and α-bisabolol oxide B for M. palustris.
    Acta Physiologiae Plantarum 08/2014; 36(8):2283-2286. DOI:10.1007/s11738-014-1562-4 · 1.52 Impact Factor
  • Source
    Reggie Lee, Carl WS, Do Couto E Silva A, Valido SE, Wu CY, Lin HW
    [Show abstract] [Hide abstract]
    ABSTRACT: Fatty acids have traditionally been described as artery clogging species that is detrimental to overall health. The most prevalent fatty acid is palmitic acid (PA), a sixteen carbon chain fatty acid that is ubiquitous in biological systems. PA is prevalent in most eukaryotic cell membranes and in the mitochondria derived from the Krebs’ cycle utilizing acetyl-coenzyme A as its’ precursor. PA is found in a variety of plants with a high amounts in coconut oil. Many cosmetics, shampoos, and commercialized beauty products contain PA providing structure and substance to the gel or reagent. An emerging field of study is the esterified form of PA or methyl palmitate, as it is involved in biological signaling in the central nervous system. More specifically, methyl palmitate or palmitic acid methyl ester can cause arterial vasodilation and is thought to be involved in neurotransmission, as well as modulate vascular tonicity in cerebral circulation. Methyl palmitate has also been implicated as a neuroprotective agent in both models of focal and global cerebral ischemia; however, the exact mechanism(s) are still unknown. We will focus on the known pharmacology, biochemistry, and clinical implications of PA and other related fatty acids (i.e. Non-esterified v. esterified fatty acids) commonly found in daily diets. Additionally, cellular target(s) of PA will be discussed as it relates to improvement of disease states, synthesis, and possible health implications/benefits of methyl palmitate in biological systems.
    Palmitic Acid: Occurrence, Biochemistry and Health Effects, Edited by Lucas F. Porto, 01/2014; Nova Science Pub Inc., ISBN: 1633215199
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: AIDS is a global pandemic that has seen the development of novel and effective treatments to improve the quality of life of those infected and reduction of spread of the disease. Palmitic Acid (PA), which we identified and isolated from Sargassum fusiforme, is a naturally occurring fatty acid that specifically inhibits HIV entry by binding to a novel pocket on the CD4 receptor. We also identified a structural analogue, 2-bromopalmitate (2-BP), as a more effective HIV entry inhibitor with a 20-fold increase in efficacy. We have used the structure-activity relationship (SAR) of 2-BP as a platform to identify new small chemical molecules that fit into the various identified active sites in an effort to identify more potent CD4 entry inhibitors. To validate further drug development, we tested the PA and 2-BP scaffold molecules for genotoxic potential. The FDA and International Conference on Harmonisation (ICH) recommends using a standardized 3-test battery for testing compound genotoxicity consisting of the bacterial reverse mutation assay, mouse lymphoma assay, and rat micronucleus assay. PA and 2-BP and their metabolites tested negative in all three genotoxicty tests. 2-BP is the first derivative of PA to undergo pre-clinical screening, which will enable us to now test multiple simultaneous small chemical structures based on activity in scaffold modeling across the dimension of pre-clinical testing to enable transition to human testing.
    PLoS ONE 03/2014; 9(3):e93108. DOI:10.1371/journal.pone.0093108 · 3.53 Impact Factor